Objective sleep measures between patients with Parkinson's disease and community-based older adults.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
04 2020
Historique:
received: 13 07 2019
revised: 18 09 2019
accepted: 19 09 2019
pubmed: 9 2 2020
medline: 22 6 2021
entrez: 9 2 2020
Statut: ppublish

Résumé

Previous studies comparing objective sleep measures between patients with Parkinson's disease (PD) and control participants were limited by their small sample size. The purpose of this study was to compare objective sleep measures between large-scale cohorts of PD outpatients and community-based older adults. In this cross-sectional study, we measured sleep parameters for 157 PD patients using an actigraph on the non-dominant wrist for six consecutive nights (95 Hoehn-Yahr stage I/II; 62 Hoehn-Yahr stage III-V). Moreover, two consecutive nights of actigraphy were performed on 1101 community-based control participants aged ≥60 years. In multivariable analysis, sleep efficiency (SE) was significantly lower in patients with late-stage PD by 17.5% [95% confidence interval: 15.3%-19.7%] and early-stage PD by 9.4% [7.6%-11.1%] compared to the controls (67.1% and 75.3% vs. 84.6%, respectively). Similar results were observed for wake after sleep onset (WASO) and fragmentation index (FI). Total sleep time and sleep onset latency (SOL) were significantly shorter in patients with late- and early-stage PD stage compared to the controls. Among PD patients, significant association trends between advancement of individual Hoehn-Yahr stages and worsened sleep measures of SE, WASO, and FI were observed independently of age, gender, levodopa equivalent dose, and motor function parameter. This study demonstrated significant and quantitative differences in objective sleep quality and quantity between PD patients and control participants. Furthermore, with advancement of disease stages, objectively measured sleep quality worsened in PD patients.

Identifiants

pubmed: 32035300
pii: S1389-9457(19)30322-3
doi: 10.1016/j.sleep.2019.09.010
pii:
doi:

Substances chimiques

Levodopa 46627O600J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-114

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Hiroshi Kataoka (H)

Department of Neurology, Nara Medical University School of Medicine, Nara, Japan. Electronic address: hk55@naramed-u.ac.jp.

Keigo Saeki (K)

Department of Epidemiology, Nara Medical University School of Medicine, Nara, Japan.

Norio Kurumatani (N)

Department of Epidemiology, Nara Medical University School of Medicine, Nara, Japan.

Kazuma Sugie (K)

Department of Neurology, Nara Medical University School of Medicine, Nara, Japan.

Kenji Obayashi (K)

Department of Epidemiology, Nara Medical University School of Medicine, Nara, Japan. Electronic address: obayashi@naramed-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH